Wittke 1999.

Methods	4‐week run‐in period 3‐month before and after trial
Participants	18 men with a lipid disorder age 38‐65 years BMI 24.2‐33.5 HDL‐C 40 mg/dL (1.03 mmol/L) exclusion criteria: none reported Fluvastatin 20 mg/day baseline TC : 8.3 mmol/L (321 mg/dL) Fluvastatin 20 mg/day baseline LDL‐C : 6.4 mmol/L (247 mg/dL) Fluvastatin 20 mg/day baseline HDL‐C : 1.15 mmol/L (44 mg/dL)
Interventions	6 men did not receive any treatment before the exercise period (control group) 6 men received fluvastatin 20 mg/day 3 months before the exercise period (pretreatment group) 6 men received fluvastatin 20 mg/day after the 4 week run‐in period from the start of the exercise period (treatment group)
Outcomes	per cent change from baseline at 3 months of serum total cholesterol, LDL‐C and HDL‐C
Source of Funding	unknown
Notes	the control and pretreatment groups were not included in the efficacy analysis for triglycerides the calculated value was different from the given data by more than 10% SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before and after design
Allocation concealment (selection bias)	High risk	Controlled before and after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	No comparison possible
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported